Biodesix Inc. is acquiring Integrated Diagnostics Inc. (Indi) for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. Terms of the deal, announced July 9, were not disclosed.
"That is perfect for us, because our primary call point is the pulmonologist and this is one of the big...